Analysis and Commentary

Find more posts:

Featured
Steven’s Final Thoughts and Where to Find Him in the Future
Steven’s Remarks on Accepting the RUF Award for His Advocacy and Policy Leadership
Republican Control in 2025 Will Prioritize Large Cuts in Federal Spending
Steven’s Traditional Thanksgiving Message to the FDA Stakeholder Community
FDA 101: What Every American Should Know (and Be Grateful For)
FDA Impacted by the Larger Transition: Some More Q&A
Presidential Transition Has Arrived at FDA: Some Q&A
Presidential Transition: Coming Soon to the FDA
Steven Is Moving On to New FDA Challenges
We Got the FY 25 CR Story Right, What’s Next? Part 2
We Got the FY 25 CR Story Right, What’s Next?
Remembrance of October 1’s Past
The Pentagon is FDA’s Ally, Really!
Establishing Reasonable Expectations for the First FY 25 CR
Q&A: Bumpy September Ride for Government Funding
September Focus on Continuing Resolution Likely to Mask Broader Budget Discussions
Hurry Up then Wait = Focus Shifts to CR in September
Are We There Yet? Appropriations Q&A for Mid-July 2024
The Alliance Expresses Concern/Disappointment with House and Senate Mark-ups
Past Analyses Provide Context for House and Senate Action on Ag-FDA Funding (Special Edition)
Two Pathways for Saving FDA’s FY 25 Budget
The Past is Prologue, But Subcommittee Bills May Not Be
What the FY 24 Appropriations Cycle Tells Us About FY 25
“Hurry Up and Wait” and Other Appropriations Questions
Three Things We Heard in Senate-side Hill Meetings
Three Things We Heard in House-side Hill Meetings
Q&A on the Urgent Need for FDA Advocacy
Escaping the Downward Budget Pressures in FY 25
The Alliance’s FY 25 Ask: Urgent Initiatives That Need More Funding
Alliance’s FY 25 Appropriations Request: Realistic for Meeting FDA’s Needs